PRINCETON, N.J., June 2 (UPI) -- Ranbaxy said Friday it has received marketing approval for a generic version of Bioglan's anti-infective Adoxa.
The India-based generic-drug firm said the Food and Drug Administration has granted market clearance for its doxycycline tablets in 50 mg, 75 mg and 100 mg strengths.
Ranbaxy estimated U.S. sales of Adoxa at $62.7 million, based on IMS Health data as of March 2006.
Doxycycline treats a variety of infections including respiratory-tract and urinary-tract infections, skin and skin-structure infections, and severe acne as adjunctive therapy, the company said.
"Ranbaxy is pleased to receive this most recent approval from the U.S. FDA. Doxycycline will add to our ever-expanding product portfolio of affordable generic alternatives that will have a positive effect on the economics of healthcare," said Jim Meehan, Ranbaxy's vice president of sales and marketing.
